XBiotech Added to Russell 3000® Index
June 11 2019 - 8:00AM
XBiotech Inc. (NASDAQ: XBIT) announced today that the Company has
been added to the preliminary list of the broad market Russell
3000® Index, which will take effect after US market close on
June 28, as part of the 2019 Russell indexes reconstitution.
Membership in the Russell 3000® Index, which remains in place for
one year, means automatic inclusion in the large-cap Russell
1000® Index or small-cap Russell 2000® Index as well as
the appropriate growth and value style indexes.
John Simard, CEO of XBiotech, stated, "We
are pleased to be added to the Russell Index and believe it
signifies recognition of the Company’s value and growth
potential."
Annual reconstitution of the Russell indexes
captures the 4,000 largest US stocks as of May 10th, ranking them
by total market capitalization. FTSE Russell determines membership
for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes. Russell
indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment
strategies. Approximately $9 trillion in assets are benchmarked
against Russell’s US indexes. Russell indexes are part of FTSE
Russell, a leading global index provider.
For more information on the Russell 3000® Index
and the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About FTSE Russell:FTSE Russell
is a leading global provider creating and managing a wide range of
indexes, data and analytic solutions to meet client needs across
asset classes, style and strategies. Covering 98% of the investable
market, FTSE Russell indexes offer a true picture of global
markets, combined with the specialist knowledge gained from
developing local benchmarks around the world.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
More than $15 trillion is currently benchmarked to FTSE Russell
indexes. For over 30 years, leading asset owners, asset managers,
ETF providers and investment banks have chosen FTSE Russell indexes
to benchmark their investment performance and create investment
funds, ETFs, structured products and index-based derivatives. FTSE
Russell indexes also provide clients with tools for asset
allocation, investment strategy analysis and risk management.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on index innovation and
customer partnership applying the highest industry standards and
embracing the IOSCO Principles. FTSE Russell is wholly owned by the
London Stock Exchange Group.For more information,
visit www.ftserussell.com.
About XBiotechXBiotech is
a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of
therapeutic antibodies based on its True Human™ proprietary
technology. XBiotech currently is advancing a robust pipeline of
antibody therapies to redefine the standards of care in oncology,
inflammatory conditions and infectious diseases. Headquartered in
Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more
rapidly, cost-effectively and flexibly produce new therapies
urgently needed by patients worldwide. For more information, visit
www.xbiotech.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements, including declarations regarding management's beliefs
and expectations that involve substantial risks and uncertainties.
In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could,"
"expects," "plans," "contemplate," "anticipates," "believes,"
"estimates," "predicts," "projects," "intend" or "continue" or the
negative of such terms or other comparable terminology, although
not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to inherent risks and
uncertainties in predicting future results and conditions that
could cause the actual results to differ materially from those
projected in these forward-looking statements. These risks and
uncertainties are subject to the disclosures set forth in the "Risk
Factors" section of certain of our SEC filings. Forward-looking
statements are not guarantees of future performance, and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
ContactAshley
Oteroaotero@xbiotech.com512-386-2930
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2023 to Apr 2024